N-Power Medicine Acquires Syapse to Expand Its Next Generation Community-Based Network for Oncology Clinical Research and Clinical Trials
Partnering with Oncologists to Unlock the Potential of Clinical Trials
Drug development takes too long. It can take 10 years1 to bring a drug to market and make its way through to the patients who need it. The challenges are multifactorial and can’t be addressed with point solutions. A new system-level model approach is needed.
Partnering with Oncologists to Unlock the Potential of Clinical Data
Routine data has the potential to transform research by tapping into critical insights from the 95% of patients not in trials. However, current real-world data (RWD) are suboptimal for drug development – opportunistically generated, incomplete, and retrospective. This limits comparisons with prospective clinical trials, even with AI, due to inconsistent and poor-quality source data.
Contemporary, standardized data is essential to inform clinical trial design, execution and interpretation and development decision-making.
N-Power Medicine’s purpose-built clinical trial platform empowers practices and biopharma companies with comprehensive solutions that increase research capacity and the availability of standardized routine care data for use in oncology drug development.
Gain Insights from the 95% of Cancer Patients Not in Trials
The N-Power Platform accelerates drug development through standardized data collection, innovative technology, and expert staffing support.
Real-time Kaleido™ Registry
ensuring data meets clinical research standards.
Innovative technology
enabling point of care data collection and analysis.
On-site and virtual staff
enhancing routine care and clinical research operations.
Addressing the Challenges to Make Clinical Trials a Reality for More Clinicians and Patients
Only 5% of patients2 are enrolled in clinical trials and there is a lack of diversity in participants.
The expanding drug pipeline strains resources at high-performing sites while oncologists’ heavy administrative burdens across practices limit their research involvement.
Because the number of drugs in development is expanding exponentially, access to clinical trials needs to expand as well.
Oncologists and oncology practices are overburdened with administrative work and lack time to engage in clinical research.
Expensive infrastructure and burdensome processes have limited clinical trial adoption for most oncology centers.
Routine-care data is not standardized and is difficult to use for clinical research1, leading to inefficient patient enrollment and reducing overall confidence in decision-making.
Drug development takes too long. It can take 10 years1 for a drug to make its way through to the patients who need it.
See the N-Power Difference
Oncology Clinics
Enable oncology practices to become high-performing clinical trial centers.
Biopharma Companies
Improve operational efficiency and generate unique data to inform and accelerate development.
Patient Advocacy Groups
Increase patient engagement and education for inclusive and effective research.
References:
- Brown DG, Wobst HJ, Kapoor A, Kenna LA, Southall N. Clinical development times for innovative drugs. Nat Rev Drug Discov. 2022 Nov;21(11):793-794. doi: 10.1038/d41573-021-00190-9. PMID: 34759309; PMCID: PMC9869766
- Unger, Joseph M., et al. “The role of clinical trial participation in cancer research: barriers, evidence, and strategies.” American Society of Clinical Oncology Educational Book 36 (2016): 185-198.